| OPPOSITION | - 3rd Declaration Giovannoni |
| OPPOSITION | - 3rd Declaration van der Graaf |
| OPPOSITION | - Alan Slade, "Abstract 293. FTY720 HIGH DOSE: LYMPHOCYTE RESPONSE AT SINGLE DOSES CP TO 40 MG", R AM J TRANSPLANT, (20040101), vol. 4, no. Suppl., page 238, XP093166908 |
| OPPOSITION | - Annex 1 of D177- Meibohm & Derendorf, Int. J. of Clinic. Pharm. and Therap., Vol. 35. No. 10 - 1997 (401-413) |
| OPPOSITION | - Ann Neurol, (20050000), vol. 58, pages 939 - 945 |
| OPPOSITION | - Anon, "FTY720, a novel once-daily oral medication, shows promising results in treatment of multiple sclerosis Press Release", (20050621), URL: www.novartis.com, (20220816), XP055951859 |
| OPPOSITION | - Anonymous , "Benzoic Acid", PubChem, (20040916), Database accession no. CID 243, XP093127586 |
| OPPOSITION | - Anonymous, "Dosage regimens: their influence on the concentration-time profile of a drug in the body", Anonymous, Michael E Aulton, Pharmaceutics: The Science of Dosage Form Design, Churchill Livingstone, (19880101), pages 191 - 195, ISBN 0-443-03643-8, XP093121473 |
| OPPOSITION | - Anonymous , "Fingolimod hydrochloride", PubChem, (20050808), Database accession no. CID 107969, XP093127583 |
| OPPOSITION | - Anonymous , "Fingolimod", PubChem, (20050808), Database accession no. CID 107970, XP093127580 |
| OPPOSITION | - Anonymous, "FTY720, a novel once-daily oral medication, shows promising results in treatment of multiple sclerosis", (20050621), pages 1 - 3, GlobeNewswire, URL: https://www.globenewswire.com/news-release/2005/06/21/1839989/0/en/FTY720-a-novel-once-daily-oral-medication-shows-promising-results-in-treatment-of-multiple-sclerosis.html, (20240119), XP093121452 |
| OPPOSITION | - Anonymous, "FTY720, a novel once-daily oral medication, shows promising results in treatment of multiple sclerosis", Novartis, (20050621), Novartis, URL: https://www.globenewswire.com/news-release/2005/06/21/1839989/0/en/FTY720-a-novel-once-daily-oral-medication-shows-promising-results-in-treatment-of-multiple-sclerosis.html, XP093163214 |
| OPPOSITION | - Anonymous, "FTY 720 - A novel oral agent for Multiple Sclerosis (MS)", Novartis, (20050621), pages 1 - 14, XP093121478 |
| OPPOSITION | - Anonymous, "FTY720 - A novel oral agent for Multiple Sclerosis (MS) - Results from a 6 month proof of concept study", (20160316), NOVARTIS, (20221024), XP055973995 |
| OPPOSITION | - Anonymous, "FTY720 - A novel oral agent for Multiple Sclerosis (MS) - Results from a 6 month proof of concept study", NOVARTIS, (20060316), NOVARTIS, (20221024), XP055973995 |
| OPPOSITION | - Anonymous, "FTY 720 - A novel oral agent for Multiple Sclerosis (MS) - results from a 6 month proof of concept study", Novartis, (20060316), pages 1 - 15, XP055973995 |
| OPPOSITION | - Anonymous, "FTY720 - A novel oral agent for Multiple Sclerosis (MS) - Results from a 6 month proof of concept study", NOVARTIS, (20160316), NOVARTIS, (20221024), XP055973995 |
| OPPOSITION | - Anonymous, "FTY720 - A novel oral agent for Multiple Sclerosis (MS): Results from a 6 month proof of concept study", Novartis Slide Presentation, (20050621), pages 1 - `14, XP055973995 |
| OPPOSITION | - Anonymous, "FTY720 Phase II 12-month data show sustained benefits and good tolerability in patients with relapsing multiple sclerosis", NOVARTIS PRESS RELEASE, (20051001), NOVARTIS PRESS RELEASE, (20221205), XP093004775 |
| OPPOSITION | - Anonymous, "General Considerations Clinical Trials E8", ICH Harmonised Tripartite Guidline, (19970717), pages 1 - 17, XP093085958 |
| OPPOSITION | - Anonymous, "Guidance for Industry - Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers", Food and Drug Administration, (20050701), pages FP - 27, URL: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM078932.pdf, (20160810), XP055294866 |
| OPPOSITION | - Anonymous, "Immunmodulator FTY 720: Viel versprechend bei multipler Sklerose", Deutsche Apotheker Zeitung (DAZ), (20050626), page 47, Deutsche Apotheker Zeitung (DAZ), URL: https://www.deutsche-apotheker-zeitung.de/daz-az/2005/daz-26-2005/uid-14188, (20190909), XP055619742 |
| OPPOSITION | - Anonymous, "Multipler Skleros (MS): Verlaufsformen - MS ind Ich", MS ind Ich, (20171102), MS ind Ich, URL: https://www.msundich.de/fuer-patienten/ms-wissen/verlaufsformen/, (20221027), XP055975434 |
| OPPOSITION | - Anonymous, "Multiple sclerosis - FTY720, a novel once-daily oral medication, shows promising results", Medical News Today, (20050626), Medical News Today, URL: https://www.medicalnewstoday.com/, (20221027), XP055975446 |
| OPPOSITION | - Anonymous, "Multiple Sclerosis - FTY720, a novel once- daily oral medication, shows promising results", Medical News Today, (20051010), pages 1 - 6, XP055975446 |
| OPPOSITION | - Anonymous, "Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis", Novartis Media Release, (20181010), Novartis Media Release, URL: https://www.novartis.com/news/media-releases/novartis-announces-new-data-from-first-direct-head-head-trial-demonstrate-superior-efficacy-gilenya-over-copaxone-patients-relapsing-remitting-multiple-sclerosis, (20221027), XP055975501 |
| OPPOSITION | - Anonymous, "Novartis shows dynamic momentum in industry-leading pipeline", Novartis press release, (20050120), Novartis press release, (20221205), XP093004786 |
| OPPOSITION | - Anonymous, "PharmaFrontiers Tovaxin(TM) phase IIb multiple sclerosis clinical tria protocol accepted by FDA", Multiple Sclerosis News Blog, (20051030), Multiple Sclerosis News Blog, (20221205), XP093004759 |
| OPPOSITION | - Anonymous, "Phase II data for FIY720 shows sustained efficacy and good tolerability over 18 months in patients with relapsing multiple sclerosis", Novartis Media Release, (20160410), pages 1 - 5, Novartis Media Release, (20221027), XP055975438 |
| OPPOSITION | - Anonymous, "Phase II data for FTY720 shows sustained efficacy and good tolerability over 18 months in patients with relapsing multiple sclerosis (MS)", (20060406), pages 1 - 3, GlobeNewswire, URL: https://www.globenewswire.com/news-release/2006/04/06/1839853/0/en/Phase-II-data-for-FTY720-shows-sustained-efficacy-and-good-tolerability-over-18-months-in-patients-with-relapsing-multiple-sclerosis-MS.html, (20240119), XP093121445 |
| OPPOSITION | - Anonymous, "Phase II Data Shows Sustained Efficiency And Good Tolerability over 18 months in patients with relapsing multiple sclerosis (MS)", (20060406), pages 1 - 4, Novartis press release, (20221205), XP093004672 |
| OPPOSITION | - Anonymous, "Phase II Data Shows Sustained Efficiency And Good Tolerability over 18 months in patients with relapsing multiple sclerosis (MS)", Novartis press release, (20060406), Novartis press release, (20221205), XP093004672 |
| OPPOSITION | - Anonymous, "Phase II Data Shows Sustained Efficiency And Good Tolerability over 18 months in patients with relapsing multiple sclerosis (MS)", Novartis press release, (20060406), XP093004672 |
| OPPOSITION | - Anonymous, "Symposia and Free Communications", Journal of Neurology. Fifteenth Meeting of the European Neurological Society, 18- 22 June 2005,, Vienna, Austria, Vienna, Austria, (20050601), vol. 252, pages 1 - 51, XP055975442 |
| OPPOSITION | - Anonymous, "The Merck Index", encyclopedia of chemicals, drugs and biologicals, (20130101), XP093004661 |
| OPPOSITION | - A. THOMSON, "Emerging Therapy Review", Core Evidence, (20060000), vol. 1, no. 3, XP055974189 |
| OPPOSITION | - BASELGA et al., "HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Ther- apeutic Implications", Oncology, (19970000), page 43, XP000978062 |
| OPPOSITION | - Baselga J., A D Seidman, P P Rosen, L Norton, "HER2 OVEREXPRESSION AND PACLITAXEL SENSITIVITY IN BREAST CANCER: THERAPEUTIC IMPLICATIONS.", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (19970301), vol. 11, no. SUPPL. 02., ISSN 0732-183X, pages 43 - 48., XP000978062 |
| OPPOSITION | - BASELGA J., ET AL., "HER2 OVEREXPRESSION AND PACLITAXEL SENSITIVITY IN BREAST CANCER: THERAPEUTIC IMPLICATIONS.", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (19970301), vol. 11., no. SUPPL. 02., ISSN 0732-183X, pages 43 - 48., XP000978062 |
| OPPOSITION | - Bettina Maunz; Corinne Hoff, "Phase II data for FTY720 shows sustained efficacy and good tolerability over 18 months in patients with relapsing multiple sclerosis (MS)", Novartis Media Release, (20060406), pages 1 - 4, XP009525587 |
| OPPOSITION | - Bettina Maunz, Corinne Hoff, "Phase II data for FTY720 shows sustained efficacy and good tolerability over 18 months in patients with relapsing multiple sclerosis (MS)", NOVARTIS Media Release, CH , (20060406), pages 1 - 4, XP009525587 |
| OPPOSITION | - Bettina Maunz, Corinne Hoff, "Phase II data for FTY720 shows sustained efficacy and good tolerability over 18 months in patients with relapsing multiple sclerosis (MS)", NOVARTIS Media Release, Novartis International AG, CH, CH , (20060406), pages 1 - 4, XP009525587 |
| OPPOSITION | - Bettina Maunz; Corinne Hoff, "Phase II data for FTZ720 shows sustained efficacy and good tolerability over 18 months in patients with relapsing multiple sclerosis", Novartis press release, (20060406), pages 1 - 4, XP009525587 |
| OPPOSITION | - BUDDE et al., "First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients", Journal of the American Society of Nephrology, (20020000), vol. 13, pages 1073 - 1083, XP003016978 |
| OPPOSITION | - BUDDE K. et al., "First human trial of FRY720, a novel immunomodulator, in stable renal transplant patients", J. Am. Soc. Nephrol., (20020000), vol. 13, pages 1073 - 1083, XP003016978 |
| OPPOSITION | - BUDDE K, ET AL., "First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients", Journal of the American Society of Nephrology, WILLIAMS AND WILKINS, BALTIMORE, MD., US, US , (20020101), vol. 13, no. 4, ISSN 1046-6673, pages 1073 - 1083, XP003016978 |
| OPPOSITION | - Cassell Dana K., "Introduction and appendix I", The Encyclopedia of Autoimmune Diseases, (20030101), pages xv - 261, XP055975519 |
| OPPOSITION | - Chavez D, "FTY720 For Relapsing Multiple Sclerosis - Phase II Data Shows Sustained Efficiency And Good Tolerability", Press release, (20060410), Press release, (20221205), XP093004676 |
| OPPOSITION | - CHIBA et al., "Role of Sphingosine 1-Phosphate Receptor Type 1 in Lymphocyte Egress from Secondary Lymphoid Tissues and Thymus", Cellular & Molecular Immunology, (20060200), vol. 3, no. 1, pages 11 - 19, XP055619721 |
| OPPOSITION | - CHIBA et al., "Role of Spingoside 1-phosphate Receptor Type 1 in Lymphocyte Egress from Secondary Lymphoid Tissues and Thymus", Cellular & Molecular Immunolo, (20060000), vol. 3, no. 1, pages 11 - 19, XP055619721 |
| OPPOSITION | - CHIBA et al., "Role of Spingoside 1-phosphate Receptor Type 1 in Lymphocyte Egress from Secondary Lymphoid Tissues and Thymus", Cellular & Molecular Immunology, (20060000), vol. 3, no. 1, pages 11 - 19, XP055619721 |
| OPPOSITION | - Chiba, Kenji, "FTY720. 2-Amino-2[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride", Drugs of the Future, Prous Science, ES, ES , (19970101), vol. 22, no. 1, ISSN 0377-8282, pages 18 - 22, XP008128504 |
| OPPOSITION | - Chiba Kenji, Matsuyuki Hirofumi, Maeda Yasuhiro, Sugahara Kunio, "Role of Sphingosine 1-Phosphate Receptor Type 1 in Lymphocyte Egress from Secondary Lymphoid Tissues and Thymus", Cellular & Molecular Immunology, Nature Publishing Group UK, London, London, (20060201), vol. 3, no. 1, ISSN 1672-7681, pages 11 - 19, XP093127593 |
| OPPOSITION | - Chiba, K., "FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors", Pharmacology & Therapeutics, ELSEVIER., GB, GB , (20051201), vol. 108, no. 3, ISSN 0163-7258, pages 308 - 319, XP027636177 |
| OPPOSITION | - Constantinescu Cris S., Farooqi N., O'brien K., Gran B., "Review - experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS", British Journal of Pharmacology, (20110101), vol. 164, pages 1079 - 1106, XP055974274 |
| OPPOSITION | - CONSTANTINESCU et al., "Review - experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS", British Journal of Pharmacology, (20110000), vol. 164, pages 1079 - 1106, XP055974274 |
| OPPOSITION | - De Gruyter Walter, "Voellig neu bearbeitete und stark erweiterte Auflage von Artur Burger und Helmut Wachter", HUNNIUS PHARMACEUTICAL LEXICON, (19930101), XP093004691 |
| OPPOSITION | - DUMONT, "Fingolimod", iDrugs, (20050000), vol. 8, no. 3, pages 236 - 253, XP009121775 |
| OPPOSITION | - Dumont, Francis J., "Fingolimod Mitsubishi Pharma/Novartis", IDrugs: The Investigational Drugs Journal, Current Drugs Ltd., GB, GB , (20050101), vol. 8, no. 3, ISSN 1369-7056, pages 236 - 253, XP009121775 |
| OPPOSITION | - Eric H Awtry, "Aspirin", Circulation, (20000314), vol. 101, no. 10, pages 1206 - 1218, XP093166927 |
| OPPOSITION | - FACIL TUNCAY AKI ET AL, "FTY720: A new kid on the block for transplant immunosuppression", (20030101), vol. 3, no. 4, pages 665 - 681, XP002323233 |
| OPPOSITION | - FARRELL R,M HEANEY D, GIOVANNONI G, "EMERGING THERAPIES IN MULTIPLE SCLEROSIS", EXPERT OPINION ON EMERGING DRUGS, Informa Healthcare, UK, UK , (20050101), vol. 10, no. 04, ISSN 1472-8214, pages 797 - 816, XP008067911 |
| OPPOSITION | - Fda, "Guideline for Industry Dose-Response Information to Support Drug Registration", FDA ICH-E4, (19941101), FDA ICH-E4, URL: https://www.fda.gov/media/71279/download, (20200514), XP055695441 |
| OPPOSITION | - Fda, "International Conference on Harmonisation: Guidance on General Considerations for Clinical Trials", Federal Register, (19971217), pages 66113 - 66119, Federal Register, (20221027), XP055975410 |
| OPPOSITION | - Fda, "Title 21 - Food and Drugs", FDA § 312.47 Meetings, (20040324), pages 1 - 2, FDA § 312.47 Meetings, URL: https://www.ecfr.gov/current/title-21/chapter-l/subchapter-D/part-312/subpart-C/section-312.47, XP093166923 |
| OPPOSITION | - Fitter Heather D, "Medical Review(s)", Center for Drug Evaluation and Research, (20091221), pages 1 - 5, XP093121465 |
| OPPOSITION | - Fleishaker Dona, Et Al, "Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-con- trolled, crossover study", BMC Musculoskeletal Disorders, (20160101), vol. 17, no. 293, pages 1 - 10, XP093022871 |
| OPPOSITION | - Form 6-K of Novartis AG |
| OPPOSITION | - Fraunhofer IME, "Experimental Autoimmune Encephalomyelitis (EAE) Rat/Mouse models for the Human inflammatory Demyelinating Disease, Multiple Sclerosis (MS)", Fraunhofer Brochure |
| OPPOSITION | - Fred Lublin, "Multiple sclerosis trial designs for the 21st century: Building on recent lessons", Journal of Neurology, Steinkopff-Verlag, DE, DE , (20051001), vol. 252, no. 5, ISSN 1432-1459, pages v46 - v53, XP019342602 |
| OPPOSITION | - "FTY720 - A novel oral agent for Multiple Sclerosis (MS)", Novartis Slide Presentation, (20050621), pages 1 - 28, XP055975526 |
| OPPOSITION | - "FTY720 for relapsing multiple sclerosis - Phase II Data shows sustained efficacy and good tolerability", MNT, (20060406), pages 1 - 5, XP009525587 |
| OPPOSITION | - GILARDI ET AL., "Novartis highlights pharmaceutical research strategy, intensifying focus on molecular pathways shared by various diseases", URL: http://cws.huginonline.com/N/134323/PR/200505/992453_5.html, (20070418), XP002429834 |
| OPPOSITION | - Goodman, Alice, "fingolimod an oral agent for ms shows promise in preliminary trails ", Neurology Today, (20060516), vol. 6, no. 10, pages 1 - 11, XP093009608 |
| OPPOSITION | - Griffins, "Purpose and Design of Clinical Trials", The Textbook of Pharmaceutical Medicine, (20060101), page 199,225, XP093004739 |
| OPPOSITION | - HART, BERT A. et al., "Evaluating the validity of animal models for research into therapies for immune-based disorders", Drug Discov. Today, (20040000), vol. 9, no. 12, pages 517 - 24, XP093022875 |
| OPPOSITION | - HARTUNG et al., "Oral Fingolimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (FORCIDP): Results from a Phase III Randomized Placebo-controlled Trial", Neurology, (20070000), vol. 88, XP055975422 |
| OPPOSITION | - HARTUNG et al., "Oral Fingolimod in Chronic Inflammatory Demyelinating Polyradiculo- neuropathy (FORCIDP): results from a phase III randomized placebo-controlled trial (S27.002", Neurology, (20170000), vol. 88, XP055975422 |
| OPPOSITION | - Hartung H-P, Marinos Dalakas, Ingemar Merkies, Norman Latov, Jean-Marc Léger, Eduardo Nobile-Orazio, Gen Sobue, Angela Genge, Martin Bernhard Merschhemke, Ervin Carolyn Marie, Catherine Agoropoulou, Richard Hughes, "Oral Fingolimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (FORCIDP): results from a phase III randomized placebo-controlled trial (S27.002", Neurology, (20170426), vol. 88, no. S37, XP055975422 |
| OPPOSITION | - Hiestand P, Schnell C, Seabrook T, Littlewood-Evans A, "Effects of FTY720 on experimental autoimmune encephalomyelitis-induced angiogenesis (acute and relapsing)", Novartis, (20090512), pages 1 - 26, XP093121462 |
| OPPOSITION | - Hiestand, Schnell, Seabrok, Littlewood-Evans, "Effects of FTY720 on experimental autoimmune encephalomyelitis-induced angiogenesis (acute and relapsing", Internal Novartis experimental, (20090512), Internal Novartis experimental, (20221027), XP055975512 |
| OPPOSITION | - Hiestand; Schnell; Seabrok; Littlewood-Evans, "Effects of FTY720 on experimental autoimmune encephalomyelitis-induced angiogenesis (acute and relapsing", Novartis experimental report, (20090512), pages 1 - 26, XP055975512 |
| OPPOSITION | - Ifnb, "Interferon beta-lb is effective in relapsing-remitting multiple sclerosis", Neurology, (19930401), vol. 43, pages 655 - 661, XP055975514 |
| OPPOSITION | - "INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS. ÖCLINICAL RESULTS OF A MULTICENTER, RANDOMIZE, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.", Neurology, Lippincott Williams & Wilkins , Philadelphia, US, US , (19930101), vol. 43., no. 04., ISSN 0028-3878, pages 655 - 661., XP000578355 |
| OPPOSITION | - J. KOVARIK et al., "Abstracts of the 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 10th Annual Meeting of Rehabilitation in Multiple Sclerosis", Multiple Sclerosis, Thessaloniki, Greece, (20050000), vol. 11, pages S1 - S182 |
| OPPOSITION | - J. Kovarik et al., "FTY720 exposure/efficiacy relationship in a 6-month phase 2 study in patients with relapsing MS", Multiple Sclerosis Journal, (2005), vol. 11, XP055973973 |
| OPPOSITION | - JONES et al., (19930000), pages 213 - 228 |
| OPPOSITION | - Journal of Neuroimmunology, (20040000), vol. 153, pages 108 - 121 |
| OPPOSITION | - Kappos E., Radü, Comi, Montalban, O Connor, Haas, Preiss, Korn, "0141. FTY720 in relapsing MS: results of a double-blind placebo- controlled trial with a novel oral immunomodulator", Journal of Neurology, (20050101), page 41, Journal of Neurology, (20221027), XP055975404 |
| OPPOSITION | - KAPPOS et al., "Design of a randomised, placebo-controlled study of oral fingolimod (FTY720) in relapsing-remitting multiple sclerosis", Journal of Neurology, (20060500), pages 1 - 4, XP055976624 |
| OPPOSITION | - KAPPOS et al., "FTY720 in relapsing MS: results of a double-blind placebo-controlled trial with a novel oral immunomodulator", Journal of Neurology, (20050000), vol. 252, page 41, XP055975404 |
| OPPOSITION | - Kappos L; Calabresi P; Hohlfeld R; Connor P O; Polman C; Aradhye S, "Design of a randomised, placebo-controlled study of oral fingolimod (FTY720) in relapsing-remitting multiple sclerosis", J. Neurol, Lausanne, Switzerland, (20060527), vol. 253, page 11, XP055976624 |
| OPPOSITION | - KATAOKA et al., "FTY720, Sphingosine-1-Phosphate Receptor Modulator, Ameliorates Experimental Autoimmune Encephalomyelitis by Inhibition of T Cell Infiltration", Cel- lular & Molecular Immunology, (20050000), vol. 2, no. 6, pages 439 - 448, XP055974232 |
| OPPOSITION | - KATAOKA et al., "The Therapeutic Effect of FTY720 On Experimental Autoimmune En- cephalomyelitis in Mice", Immunology, (20040000), pages 87 - 89, XP055974229 |
| OPPOSITION | - Kataoka Hirotoshi, Sugahara Kunio, Shimano Kyoko, Teshima Koji, Koyama Mamoru, Fukunari Atsushi, Chiba Kenji, "FTY720, Sphingosine 1-Phosphate Receptor Modulator, Ameliorates Experimental Autoimmune Encephalomyelitis by Inhibition of T Cell Infiltration", Cellular & Molecular Immunology, (20051201), vol. 2, no. 6, pages 439 - 448, XP055974232 |
| OPPOSITION | - Kataoka H., Sugahara K., Tanaka H., Ohtsuki M., Maeda Y., Murata M., Shimano K., Chiba K., "The Therapeutic Effect of FIY720 On Experimental Autoimmune Encephalomyelitis in Mice", Immunology, (20040701), pages 87 - 89, Immunology, (20221024), XP055974229 |
| OPPOSITION | - Kenji Chiba, Matsuyuki Hirofumi, Maeda Yasuhiro, Sugahara Kunio, "Cellular & Molecular Immunology 11 Role of Sphingosine 1-Phosphate Receptor Type 1 in Lymphocyte Egress from Secondary Lymphoid Tissues and Thymus", Cellular & Molecular Immunology, (20060201), vol. 3, no. 1, pages 11 - 19, XP055619721 |
| OPPOSITION | - Klemens Budde et al., "First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients", Journal of the American Society of Nephrology, (2002), vol. 13, XP003016978 |
| OPPOSITION | - Konrad Diem, Cornelius Lentner , "leukozyten ", Wissenschaftliche Tabellen, (19750101), page 615, XP093005153 |
| OPPOSITION | - Kovarik, "abstract 612: Associations between FTY720 blood levels vs lymphopenia and acute rejection episodes in de novo kidney transplantation", American Journal of Transplantation. Congress May 30 June 4, 2003, (20030530), page 308, American Journal of Transplantation. Congress May 30 June 4, 2003, (20221024), XP055974221 |
| OPPOSITION | - KOVARIK et al., "Associations between FTY720 blood levels vs lymphopenia and acute rejection episodes in de novo kidney transplantation", American Journal of Trans- plantation, (20030000), vol. 3, no. s5, page 308, XP055974221 |
| OPPOSITION | - KOVARIK et al., "Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects", British Journal of Clinical Pharmacology, (20040000), vol. 57, no. 5, pages 586 - 591, XP093007128 |
| OPPOSITION | - KOVARIK J et al., "FTY720 exposure/efficacy relationship in a 6-month phase 2 study in patients with relapsing MS", Multiple Sclerosis, (20050000), vol. 11, page S152, XP055973973 |
| OPPOSITION | - Kovarik J, H. Schmidli, E.-W Radu, F. Antel, G. Cami, X. Montalban, Pw O'connor, J Kuhle, A. Korn, T Haas, L. Kappos, "P578 FTY720 exposure/efficacy relationship in a month phase 2 study in patients with relapsing MS", Multiple Sclerosis, (20050101), vol. 11, pages S152 - S152, XP093121440 |
| OPPOSITION | - Kovarik J M, Et Al, "FTY720 Pharmacokinetics in Mild to Moderate Hepatic Impairment", J Clin Pharmacol, (20050101), vol. 45, pages 446 - 452, XP093067002 |
| OPPOSITION | - Kovarik, "P578 - FTY720 published 31 October 2005 or exposure/efficacy relationship in a 6-month earlier phase 2 study in patients with relapsing MS", Therapy - immunomodulation, (20051001), vol. 11, no. 5, page s152, XP055973973 |
| OPPOSITION | - Kovarik, "P578 - FTY720 published or exposure/efficacy relationship in a 6-month earlier phase 2 study in patients with relapsing MS", Therapy - immunomodulation, (20051001), vol. 11, no. 5, page s152, XP055973973 |
| OPPOSITION | - Lawrence J Lesko, "Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans", European Journal of Pharmaceutical Sciences, (20000601), vol. 10, no. 4, pages iv - xiv, XP093166918 |
| OPPOSITION | - L Kappos, "Abstract 64. Promising results with a novel oral immunomodulator-FTY720-in relapsing multiple sclerosis", Multiple Sclerosis, (20050901), vol. 11, no. 5, page S13, XP093166913 |
| OPPOSITION | - L. Kappos et al., "Design of randomized, placebo-controlled study of oral fingolimod (FTY720) in relapsing-remitting multiple sclerosis", Journal of Neurology, (2006), vol. 253, XP055976624 |
| OPPOSITION | - L. Kappos, P. Calabresi, R. Hohlfeld, P.O Connor, C. Polman, S. Aradhye, "P569 : Design of a randomised, placebo-controlled study of oral fingolimod (FTY720) in relapsing-remitting multiple sclerosis", Journal of Neurology, (20060101), vol. 253, no. Suppl.2, pages II/2, II/143 - II/144, XP055976624 |
| OPPOSITION | - LUBLIN, "Multiple sclerosis trial designs for the 21st century: Building on recent les- sons", Journal of Neurology, (20050000), vol. 252, pages 46 - 53, XP019342602 |
| OPPOSITION | - LUBLIN, "Multiple sclerosis trial designs for the 21st century: Building on recent lessons", Journal of Neurology, (20050000), vol. 252, XP019342602 |
| OPPOSITION | - Maunz Bettina, Hoff Corinne, "Phase II data for FTY720 shows sustained efficacy and good tolerability over 18 months in patients with relapsing multiple sclerosis (MS)", Novartis press release, (20060406), pages 1 - 4, Novartis press release, (20240115), XP093119227 |
| OPPOSITION | - M J Phillips, M Needham, R O Weller, "Role of cervical lymph nodes in autoimmune encephalomyelitis in the Lewis rat", Journal of Pathology, (19970101), vol. 182, pages 457 - 464, XP055975786 |
| OPPOSITION | - M K Storch, "P188 FTY720 not only prevents EAE onset, as assessed by MRI, but also reverses established neurological deficits and extensive demyelination", Multiple Sclerosis Journal, (20160321), vol. 11, no. 5, page S45, XP093166902 |
| OPPOSITION | - "Novartis announces new data from the first direct head-to- head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis", Novartis Media Release, (20181010), XP055975501 |
| OPPOSITION | - "Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis", Novartis Media Release, (20181010), XP055975501 |
| OPPOSITION | - Novartis, "FTY720 - A novel oral agent for Multiple Sclerosis (MS)", Novartis Slide Presentation, (20050621), pages 1 - 28, Novartis Slide Presentation, (20221027), XP055975526 |
| OPPOSITION | - Novartis, "FTY720 - A novel oral agent for Multiple Sclerosis (MS)", Novartis Slide Presentation, (20050621), pages 1 - 28, XP055975526 |
| OPPOSITION | - Novartis, "FTY 720 - A novel oral agent for Multiple Sclerosis (MS)- Results from a 6 month proof of concept study", Novartis presentation, (20060316), pages 1 - 14, Novartis presentation, (20240115), XP093119229 |
| OPPOSITION | - Oneil, Heckelman, Koch, Roman, "Fingolimod", THE MERCK INDEX. 14th ed., (20060101), page 4088, XP055975401 |
| OPPOSITION | - PARK et al., "Peripheral Blood FTY720, Pharmacokinetic/Pharmacodynamic ( PK /PD) Modeling in Renal Transplanted Recipients, Abstract #707, Kidney: Pharmacogenetics, Kinetics and New Drug", American Journal of Transplantation, (20030000), page 333, XP055975505 |
| OPPOSITION | - PARK et al., "Peripheral blood FTY720 pharmacokinetic/pharmacodynamic ( PK /PD) modeling in renal transplanted recipients", American Journal of Transplantation, (20030000), vol. 3, no. S5, page 333, XP055975505 |
| OPPOSITION | - Park . I., Felipe, Machado, Garcia, Skerjanec, Schmouder, Tedesco-Silva, Medina-Pestana, "707. Peripheral blood FTY720 pharmacokinetic/pharmacodynamic ( PK /PD) modeling in renal transplanted recipients", American Journal of Transplantation, (20030101), page 333, American Journal of Transplantation, (20221027), XP055975505 |
| OPPOSITION | - Preliminary opinion issued in T 108/21 |
| OPPOSITION | - Racke Michael K, "Experimental Autoimmune Encephalomyelitis (EAE)", Current Protocols in Neuroscience, (20010101), vol. 9.7, pages 1 - 11, XP093022876 |
| OPPOSITION | - Rice Jocelyn, "Animal models: Not close enough", nature, (20120411), vol. 484, no. 59, pages 1 - 7, XP093022869 |
| OPPOSITION | - Rudolf M.Schmidt, Frank A. Hoffmann, "16.4 immunsuppression ", multiple sklerose , (20060101), pages 283 - 286, XP093005152 |
| OPPOSITION | - Tedesco-Silva Helio, Et Al, "FTY720, A NOVEL IMMUNOMODULATOR: EFFICACY AND SAFETY RESULTS FROM THE FIRST PHASE 2A STUDY IN DE NOVO RENAL TRANSPLANTATION", Transplantation, (20040627), vol. 77, no. 12, pages 1826 - 1833, XP093067005 |
| OPPOSITION | - TESHIMA et al., "FTY720, a novel immunosuppressant, possessing unique mecha- nisms. III. Pharmacological activities in several autoimmune and inflammatory mod- els", 9th International Congress of Immunology, (19950000), XP055975508 |
| OPPOSITION | - TESHIMA et al., "FTY720, a Novel Immunosuppressant, Possessing Unique Mechanisms, Pharmacological activities in several autoimmune and inflammatory models", 9th International Congress of Immunology, (19950000), XP055975508 |
| OPPOSITION | - Teshima, Fuji, Suzuki, Agachi, Mishina, Sasaki, Fujita, "5125. FTY720, a novel immunosuppressant, possessing unique mechanisms. III. Pharmacological activities in several autoimmune and inflammatory models", 9th International Congress of Immunology, California, California, (19950723), XP055975508 |
| OPPOSITION | - Thomas N Tozfr, "Detecting Time Delays", Introduction to Pharmacokinetics and Pharmacodynamics - The Quantitative Basis of Drug Therapy, Lippincott Williams & Wilkins , (20060101), pages 138 - 140, 189, ISBN 978-0-7817-5149-0, XP093166916 |
| OPPOSITION | - THOMSON A., "Emerging therapy review: FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value", Core Evidence, (20060000), vol. 1, no. 3, XP055974189 |
| OPPOSITION | - Thomson Andrew, "Emerging therapy review: FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value", Core Evid ., (20060331), vol. 1, no. 3, pages 157 - 167, XP055974189 |
| OPPOSITION | - Thomson Andrew, "Emerging therapy review FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value", Core Evidence, (20060101), vol. 1, no. 3, pages 157 - 167, XP093119226 |
| OPPOSITION | - Thomson Andrew, "Emerging therapy review - FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value", Core Evidence, (20060101), vol. 1, no. 3, pages 157 - 167, XP093127568 |
| OPPOSITION | - Thomson Andrew, "FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value", Core Evidence, (20060101), vol. 1, no. 3, pages 157 - 167, XP093121432 |
| OPPOSITION | - THOMSON ANDREW, "FTY720 IN MULTIPLE SCLEROSIS: THE EMERGING EVIDENCE OF ITS THERAPEUTIC VALUE", CORE EVIDENCE, CORE MEDICAL PUBLISHING, WHITE PLAINS, NY, US, US , (20060301), vol. 1, no. 3, ISSN 1555-1741, pages 157 - 167, XP001247375 |
| OPPOSITION | - THOMSON, "Emerging therapy review: FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value", Core Evidence, (20060000), vol. 1, no. 3, pages 157 - 167, XP055974189 |
| OPPOSITION | - TRENDS in Immunology, (20051100), vol. 26, no. 11 |
| OPPOSITION | - URBAN et al., "Immunosuppression", Multiple Sklerose, Munchen, (20060000), pages 283 - 286 |
| OPPOSITION | - URL: https://clinicaltrials.gov/ct2/show/NCTD7200355134 |
| OPPOSITION | - WHITEHEAD J., "Perspectives: Stopping clinical trials by design, Nature Reviews", Drug Discovery, (20040000), vol. 3, pages 973 - 977 |
| OPPOSITION | - Wissenschaftliche Tabellen, Stuttgart, (19750000), page 615 |
| OPPOSITION | - GIJBELS et al., "Experimental autoimmune encephalomyelitis: an animal model for multiple sclerosis", Neuroscience Research Communications, (20000000), vol. 26, no. 3, doi:10.1002/1520-6769(200005/06)26:3<193::AID-NRC7>3.0.CO;2-5, pages 193 - 206, XP055974273 |
| OPPOSITION | - Gijbels K., Engelborghs S., De Deyn P.P., "Experimental autoimmune encephalomyelitis: An animal model for multiple sclerosis", Neuroscience research communications, GB , (20000501), vol. 26, no. 3, doi:10.1002/1520-6769(200005/06)26:3<193::AID-NRC7>3.0.CO;2-5, ISSN 0893-6609, pages 193 - 206, XP055974273 |
| OPPOSITION | - Gijbels K., Engelborghs S., De Deyn P.P., "Experimental autoimmune encephalomyelitis: An animal model for multiple sclerosis", NEUROSCIENCE RESEARCH COMMUNICATIONS., GB , (20000501), vol. 26, no. 3, doi:10.1002/1520-6769(200005/06)26:3<193::AID-NRC7>3.0.CO;2-5, ISSN 0893-6609, pages 193 - 206, XP055974273 |
| OPPOSITION | - Gijbels K., Engelborghs S., De Deyn P.P., "Experimental autoimmune encephalomyelitis: An animal model for multiple sclerosis", NEUROSCIENCE RESEARCH COMMUNICATIONS., WILEY, CHICHESTER,, GB, GB , (20000501), vol. 26, no. 3, doi:10.1002/1520-6769(200005/06)26:3<193::AID-NRC7>3.0.CO;2-5, ISSN 0893-6609, pages 193 - 206, XP055974273 |
| OPPOSITION | - GIJBELS K. et al., "Experimental Autoimmune Encephalomyelitis: an animal model for multiple sclerosis", Neuroscience Research Communications, (20000000), vol. 26, doi:10.1002/1520-6769(200005/06)26:3<193::AID-NRC7>3.0.CO;2-5, pages 193 - 206, XP055974273 |
| OPPOSITION | - SRIRAM S., "Experimental Allergic Encephalomyelitis: A Misleading Model of Multiple Sclerosis", Ann Neurol, (20050000), vol. 58, no. 6, doi:10.1002/ana.20743, pages 939 - 45, XP071637903 |
| OPPOSITION | - Lawrence Steinman; Scott S. Zamvil, "How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis", Annals of Neurology, John Wiley and Sons, Boston , US, Boston , US , (20060626), vol. 60, no. 1, doi:10.1002/ana.20913, ISSN 0364-5134, pages 12 - 21, XP071638370 |
| OPPOSITION | - COOK et al., "Total Lymphoid Irradiation in Multiple Sclerosis: Blood Lymphocytes and Clinical Course", Annals of Neurology, (19870000), vol. 22, no. 5, doi:10.1002/ana.410220513, pages 634 - 638, XP055975280 |
| OPPOSITION | - Cook Stuart D., Devereux Corinne, Troiano Raymond, Zito George, Hafstein Marino, Lavenhar Marvin, Hernandez Enrique, Dowling Peter C., "Total lymphoid irradiation in multiple sclerosis: Blood lymphocytes and clinical course", Annals of Neurology, Boston , US , (19871101), vol. 22, no. 5, doi:10.1002/ana.410220513, ISSN 0364-5134, pages 634 - 638, XP055975280 |
| OPPOSITION | - Cook Stuart D., Devereux Corinne, Troiano Raymond, Zito George, Hafstein Marino, Lavenhar Marvin, Hernandez Enrique, Dowling Peter C., "Total lymphoid irradiation in multiple sclerosis: Blood lymphocytes and clinical course", Annals of Neurology, John Wiley and Sons, Boston , US, Boston , US , (19871101), vol. 22, no. 5, doi:10.1002/ana.410220513, ISSN 0364-5134, pages 634 - 638, XP055975280 |
| OPPOSITION | - Kalliopi Pitarokoili et al., "Lewis Rat Model of Experimental Autoimmune Encephalomyelitis", Current Protocols in Neurosciences, (2017), vol. S81, XP055974275 |
| OPPOSITION | - PITAROKOILI et al., "Lewis Rat Model of Experimental Autoimmune Encephalomyelitis", Current Protocols in Neuroscience, (20170000), pages 1 - 21, XP055974275 |
| OPPOSITION | - Pitarokoili Kalliopi; Ambrosius Bjoern; Gold Ralf, "Lewis Rat Model of Experimental Autoimmune Encephalomyelitis", Current Protocols in Neuroscience, (20170000), vol. 81, no. 1, pages 1 - 21, XP055974275 |
| OPPOSITION | - Pitarokoili Kalliopi, Ambrosius Bjoern, Gold Ralf, "Lewis Rat Model of Experimental Autoimmune Encephalomyelitis", Current Protocols in Neuroscience, (20171001), vol. 81, no. 1, doi:10.1002/cpns.36, ISSN 1934-8584, XP055974275 |
| OPPOSITION | - Gary L. C. Chan, "The Therapeutic Use of Azathioprine in Renal Transplantation", Pharmacotherapy, Wiley-Blackwell, US, US , (19870910), vol. 7, no. 5, doi:10.1002/j.1875-9114.1987.tb04046.x, ISSN 0277-0008, pages 165 - 177, XP093166921 |
| OPPOSITION | - RAUSCH et al., "Predictability of FTY720 Efficacy in Experimental Autoimmune Enceph- alomyelitis by In Vivo Macrophage Tracking: Clinical Implications for Ultrasmall Su- perparamagnetic Iran Oxide-Enhanced Magnetic Resonance Imaging", Journal of Magnetic Resonance Imaging, (20040000), vol. 20, pages 16 - 24, XP055974224 |
| OPPOSITION | - RAUSCH et al., "Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging", Journal of magnetic resonance imaging, (20040000), vol. 20, doi:10.1002/jmri.20057, pages 16 - 24, XP055974224 |
| OPPOSITION | - Rausch Martin, Hiestand Peter, Foster Carolyn A., Baumann Diana R., Cannet Catherine, Rudin Markus, "Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: Clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging", JOURNAL OF MAGNETIC RESONANCE IMAGING, SOCIETY FOR MAGNETIC RESONANCE IMAGING, OAK BROOK, IL,, US, US , (20040701), vol. 20, no. 1, doi:10.1002/jmri.20057, ISSN 1053-1807, pages 16 - 24, XP055974224 |
| OPPOSITION | - M. Rausch, "MRI‐based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE", Magnetic resonance in medicine, Wiley-Liss, US, US , (20030717), vol. 50, no. 2, doi:10.1002/mrm.10541, ISSN 0740-3194, pages 309 - 314, XP093166903 |
| OPPOSITION | - KUROSE et al., "Effects of FTY720, a Novel Immunosuppressant, on Experimental Au- toimmune Uveoretinitis in Rats", Experimental Eye Researc h, (20000000), vol. 70, no. 1, pages 7 - 15, XP002382822 |
| OPPOSITION | - KUROSE S, ET AL, "Effects of FTY720 a novel immunosppressant on Experimental Autoimmune Uveorentitis in rats.", Experimental Eye Research, ACADEMIC PRESS LTD., LONDON., LONDON. , (20000101), vol. 70, no. 7, doi:10.1006/exer.1999.0777, ISSN 0014-4835, pages 7 - 15, XP002382822 |
| OPPOSITION | - FEURER C. et al., "Chronic Relapsing Experimental Allergic Encephalomyelitis in the Lewis Rat", Journal of Neuroimmunology, (19850000), vol. 10, doi:10.1016/0165-5728(85)90006-2, pages 159 - 166, XP023789446 |
| OPPOSITION | - Michael Webb et al., "Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice", Journal of Neuroimmunology, (2004), vol. 153, doi:10.1016/j.jneuroim.2004.04.015, XP055975413 |
| OPPOSITION | - Webb et al. null, "Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice", Journal of Neuroimmunology , (2004), vol. 153, doi:10.1016/j.jneuroim.2004.04.015, XP055975413 |
| OPPOSITION | - WEBB et al., "Sphingosine 1-phosphate receptor agonists attenuate relapsing- remitting experimental autoimmune encephalitis in SJL mice", Journal of Neuroimmunology, (20040000), vol. 153, doi:10.1016/j.jneuroim.2004.04.015, pages 108 - 121, XP055975413 |
| OPPOSITION | - WEBB et al., "Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice", Journal of Neuroimmunology, (20040000), vol. 153, doi:10.1016/j.jneuroim.2004.04.015, pages 108 - 121, XP055975413 |
| OPPOSITION | - WEBB et al., "Sphingosine 1-phosphate receptor agonists attenuate relapsing- remit- ting experimental autoimmune encephalitis in SJL mice", Journal of Neuroimmunol- ogy, (20040000), vol. 153, pages 108 - 121, XP055975413 |
| OPPOSITION | - WEBB et al., "Sphingosine I-phosphate receptor agonists attenuate relapsing remitting experimental autoimmune encephalitis in SJL mice", Journal of Neuroimmunology, (20040000), vol. 153, doi:10.1016/j.jneuroim.2004.04.015, pages 108 - 121, XP055975413 |
| OPPOSITION | - WEBB M. et al., "Sphingosine 1-phosphate receptor agonists attenuate relapsing- remitting experimental autoimmune encephalitis in SJL mice", Journal of Neuroimmunology, (20040000), vol. 153, doi:10.1016/j.jneuroim.2004.04.015, pages 108 - 121, XP055975413 |
| OPPOSITION | - Webb Michael, Tham Chui-Se, Lin Fen-Fen, Lariosa-Willingham Karen, Yu Naichen, Hale Jeffrey, Mandala Suzanne, Chun Jerold, Rao Tadimeti S, "Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice", Journal of Neuroimmunology, ELSEVIER SCIENCE PUBLISHERS BV., NL, NL , (20040801), vol. 153, no. 1-2, doi:10.1016/j.jneuroim.2004.04.015, ISSN 0165-5728, pages 108 - 121, XP055975413 |
| OPPOSITION | - Webb Michael, Tham Chui-Se, Lin Fen-Fen, Lariosa-Willingham Karen, Yu Naichen, Hale Jeffrey, Mandala Suzanne, Chun Jerold, Rao Tadimeti S, "Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice", Journal of Neuroimmunology, NL , (20040801), vol. 153, no. 1-2, doi:10.1016/j.jneuroim.2004.04.015, ISSN 0165-5728, pages 108 - 121, XP055975413 |
| OPPOSITION | - Mohajeri Maryam; Sadeghizadeh Majid; Javan Mohammad, "Pertussis toxin promotes relapsing-remitting experimental autoimmune encephalomyelitis in Lewis rats", Journal of Neuroimmunology, NL , (20151111), vol. 289, doi:10.1016/j.jneuroim.2015.10.012, ISSN 0165-5728, pages 105 - 110, XP029313741 |
| OPPOSITION | - KIRK et al., "Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon", Journal of the Neurological Sciences, (20040000), vol. 217, doi:10.1016/j.jns.2003.10.016, pages 125 - 130, XP055974277 |
| OPPOSITION | - KIRK et al., "Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon?", Journal of the Neurological Sciences, (20040000), vol. 217, no. 2, doi:10.1016/j.jns.2003.10.016, pages 125 - 130, XP055974277 |
| OPPOSITION | - KIRK S. et al., "Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon", Neurol Sci, (20040215), vol. 217, no. 2, doi:10.1016/j.jns.2003.10.016, pages 125 - 30, XP055974277 |
| OPPOSITION | - Kirk Shauna, Frank Joseph A., Karlik Stephen, "Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon?", JOURNAL OF NEUROLOGICAL SCIENCES., ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM., NL, NL , (20040201), vol. 217, no. 2, doi:10.1016/j.jns.2003.10.016, ISSN 0022-510X, pages 125 - 130, XP055974277 |
| OPPOSITION | - Kirk Shauna, Frank Joseph A., Karlik Stephen, "Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon?", Journal of Neurological sciences, NL , (20040201), vol. 217, no. 2, doi:10.1016/j.jns.2003.10.016, ISSN 0022-510X, pages 125 - 130, XP055974277 |
| OPPOSITION | - CHIBA, "FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors", Pharmacology & Therapeutics, (20050000), vol. 108, doi:10.1016/j.pharmthera.2005.05.002, pages 308 - 319, XP005186745 |
| OPPOSITION | - CHIBA, "FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phos- phate receptors", Pharmacology & Therapeutics, (20050000), vol. 108, pages 308 - 319, XP005186745 |
| OPPOSITION | - Kahan B.D., "FTY720: a new immunosuppressive agent with novel mechanism(s) of action", TRANSPLANTATION PROCEEDINGS, Elsevier Inc., ORLANDO, FL; US, ORLANDO, FL; US , (19980801), vol. 30, no. 5, doi:10.1016/S0041-1345(98)00593-4, ISSN 0041-1345, pages 2210 - 2213, XP055974266 |
| OPPOSITION | - Kahan B.D., "FTY720: a new immunosuppressive agent with novel mechanism(s) of action", TRANSPLANTATION PROCEEDINGS, ORLANDO, FL; US , (19980801), vol. 30, no. 5, doi:10.1016/S0041-1345(98)00593-4, ISSN 0041-1345, pages 2210 - 2213, XP055974266 |
| OPPOSITION | - KAHAN, "FTY720: A New Immunosuppressive Agent With Novel Mechanism(s) of Action", Transplantation Proceedings, (19980000), vol. 30, no. 5, doi:10.1016/S0041-1345(98)00593-4, pages 2210 - 2213, XP055974266 |
| OPPOSITION | - Kahan null, "FTY720: A New Immunosuppressive Agent With Novel Mechanism(s) of Action", Transplantation Proceedings, (1998), vol. 30, doi:10.1016/S0041-1345(98)00593-4, XP055974266 |
| OPPOSITION | - CHIBA et al., "FTY720, a Novel Immunosuppressant, Induces Sequestration of Circu- lating Lymphocytes by Acceleration of Lymphocyte Homing", Transplantation Pro- ceedings, (19990000), vol. 31, pages 1230 - 1233, XP055974241 |
| OPPOSITION | - CHIBA K. et al., "FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing", Transplantation proceedings, (19990000), vol. 31, doi:10.1016/S0041-1345(98)01975-7, pages 1230 - 1233, XP055974241 |
| OPPOSITION | - Chiba K, Yanagawa Y, Kataoka H, Kawaguchi T, Ohtsuki M, Hoshino Y, "FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing", TRANSPLANTATION PROCEEDINGS, Elsevier Inc., ORLANDO, FL; US, ORLANDO, FL; US , (19990201), vol. 31, no. 1-2, doi:10.1016/S0041-1345(98)01975-7, ISSN 0041-1345, pages 1230 - 1233, XP055974241 |
| OPPOSITION | - K. Chiba et al., "FTY720, a Novel Immunosuppressant, Induces Sequestration of Circulating Lymphocytes by Acceleration of Lymphocyte Homing", Transplantation Proceedings, (1999), vol. 31, doi:10.1016/S0041-1345(98)01975-7, XP055974241 |
| OPPOSITION | - LUBLIN et al., "Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo- controlled trial", Lancet, (20160000), vol. 387, doi:10.1016/S0140-6736(15)01314-8, pages 1075 - 84, XP029442340 |
| OPPOSITION | - LUBLIN et al., "Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial", Lancet, (20160000), vol. 387, doi:10.1016/S0140-6736(15)01314-8, pages 1075 - 84, XP029442340 |
| OPPOSITION | - LUBLIN et al., "Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial", The Lance t, (20160000), vol. 387, doi:10.1016/S0140-6736(15)01314-8, pages 1075 - 1084, XP029442340 |
| OPPOSITION | - Lublin Fred; Miller David H; Freedman Mark S; Cree Bruce A C; Wolinsky Jerry S; Weiner Howard; Lubetzki Catherine; Hartung Hans-Peter; Montalban Xavier; Uitdehaag Bernard M J; Merschhemke Martin; Li Bingbing; Putzki Norman; Liu Fonda C; Häring Dieter A; Kappos Ludwig, "Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20160128), vol. 387, no. 10023, doi:10.1016/S0140-6736(15)01314-8, ISSN 0140-6736, pages 1075 - 1084, XP029442340 |
| OPPOSITION | - Quesniaux Valerie, Fullard Lynn, Arendse Hiram, Davison Glenda, Markgraaff Noel, Auer Roland, Ehrhart Francis, Kraus Gerolf, Schuurman Henk-Jan, "A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons", Transplant Immunology, Elsevier, NL, NL , (19990901), vol. 7, no. 3, doi:10.1016/S0966-3274(99)80034-3, ISSN 0966-3274, pages 149 - 157, XP055974233 |
| OPPOSITION | - BOUÉRAT et al., "Indolin-2-ones with High in Vivo Efficacy in a Model for Multiple Scle- rosis", Journal of Medicinal Chemistry, (20050000), vol. 48, no. 17, pages 5412 - 5414, XP055974269 |
| OPPOSITION | - BOUERAT et al., "Infolin-2-ones with high in vivo efficacy in a model for multiple sclerosis", Journal of Medicinal Chemistry, (20050000), vol. 48, doi:10.1021/jm0504151, pages 5412 - 5414, XP055974269 |
| OPPOSITION | - Bouérat Laëtitia, Fensholdt Jef, Liang Xifu, Havez Sophie, Nielsen Simon F., Hansen Jens R., Bolvig Simon, Andersson Christina, "Indolin-2-ones with High in Vivo Efficacy in a Model for Multiple Sclerosis", Journal of Medicinal Chemistry, American Chemical Society, US, US , (20050801), vol. 48, no. 17, doi:10.1021/jm0504151, ISSN 0022-2623, pages 5412 - 5414, XP055974269 |
| OPPOSITION | - BUDDE et al., "Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients", American Journal of Transplantation, (20030000), vol. 3, doi:10.1034/j.1600-6143.2003.00130.x, pages 846 - 854, XP055664232 |
| OPPOSITION | - Klemens Budde et al., "Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients", American Journal of Transplantation, (2003), vol. 3, doi:10.1034/j.1600-6143.2003.00130.x, XP055664232 |
| OPPOSITION | - Klemens Budde, Robert L. Schmouder, Bjorn Nashan, Reinhard Brunkhorst, Peter W. Lucker, Thomas Mayer, Laurence Brookman, Jerry Nedelman, Andrej Skerjanec, Torsten Bohler, Hans-Hellmut Neumayer, "Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients", American journal of transplantation, BLACKWELL MUNKSGAARD, DK, DK , (20030701), vol. 3, no. 7, doi:10.1034/j.1600-6143.2003.00130.x, ISSN 1600-6135, pages 846 - 854, XP055664232 |
| OPPOSITION | - Klemens Budde, Robert L. Schmouder, Bjorn Nashan, Reinhard Brunkhorst, Peter W. Lucker, Thomas Mayer, Laurence Brookman, Jerry Nedelman, Andrej Skerjanec, Torsten Bohler, Hans-Hellmut Neumayer, "Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients", American journal of transplantation, DK , (20030701), vol. 3, no. 7, doi:10.1034/j.1600-6143.2003.00130.x, ISSN 1600-6135, pages 846 - 854, XP055664232 |
| OPPOSITION | - POTTER et al., "Past versus present: the importance of tense in patent application examples", Nature Biotechnology, (20030000), vol. 21, no. 11, doi:10.1038/nbt1103-1397, pages 1397 - 1398, XP055020529 |
| OPPOSITION | - POTTER J.E.R. et al., "Past versus present: the importance of tense in patent application examples", Nature Biotechnology, (20030000), vol. 21, doi:10.1038/nbt1103-1397, pages 1397 - 1398, XP055020529 |
| OPPOSITION | - L. KAPPOS et al., "Oral fingolimod (FTY720) for relapsing multiple sclerosis", N Engl J Med, (20060914), vol. 355, no. 11, doi:10.1056/NEJMoa052643, pages 1124 - 40, XP009072986 |
| OPPOSITION | - L. KAPPOS et al., "Oral fingolimod (FTY720) for relapsing multiple sclerosis", N Engl J Med., (20060914), vol. 355, no. 11, doi:10.1056/NEJMoa052643, pages 1124 - 40, XP009072986 |
| OPPOSITION | - Jeffrey A Cohen; M D; Frederik Barkhof; M D; Giancarlo Corni; ET AL, "Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis", The New England Journal of Medicine, (20100100), vol. 362, pages 402 - 415, XP009525586 |
| OPPOSITION | - Jeffrey A. Cohen, M.D., Frederik Barkhof, M.D., Giancarlo Corni et al., "Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis", The New England journal of medicine, Massachusetts Medical Society, US, US , (20100204), vol. 362, no. 5, doi:10.1056/NEJMoa0907839, ISSN 0028-4793, pages 402 - 415, XP009525586 |
| OPPOSITION | - Jeffrey A. Cohen, Frederik Barkhof, Giancarlo Comi, Hans-Peter Hartung, Bhupendra O. Khatri, Xavier Montalban, Jean Pelletier, Ruggero Capra, Paolo Gallo, Guillermo Izquierdo, Klaus Tiel-Wilck, Ana de Vera, James Jin, Tracy Stites, Stacy Wu, Shreeram Aradhye, Ludwig Kappos, "Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20100204), vol. 362, no. 5, doi:10.1056/NEJMOA0907839, ISSN 1533-4406, pages 402 - 415, XP002630421 |
| OPPOSITION | - TAMURA A, ET AL., "IMMUNOSUPPRESSIVE THERAPY USING FTY720 COMBINED WITH TACROLIMUS IN RAT LIVER TRANSPLANTATION", SURGERY, Mosby, Inc., US, US , (20000101), vol. 127, no. 01, doi:10.1067/msy.2000.100884, ISSN 0039-6060, pages 47 - 54, XP009022839 |
| OPPOSITION | - BRINKMANN et al., "The immune modulator FTY720 targets sphingosine 1-phosphate receptors", Journal of Biological Chemistry, (20220600), vol. 277, no. 24, doi:10.1074/jbc.C200176200, pages 21453 - 21457, XP002264445 |
| OPPOSITION | - BRINKMANN et al., "T he Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors", The Journal of Biological Chemistry, (20020000), vol. 227, no. 24, doi:10.1074/jbc.C200176200, pages 21453 - 21457, XP002264445 |
| OPPOSITION | - BRINKMANN et al., "The Immune Modulator FTY720 Targets Sphingosine 1- Phosphate Receptors", The Journal of Biological Chemistry, (20020000), vol. 227, no. 24, doi:10.1074/jbc.C200176200, pages 21453 - 21457, XP002264445 |
| OPPOSITION | - BRINKMANN VOLKER ET AL, "The immune modulator FTY720 targets sphingosine 1-phosphate receptors", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20020614), vol. 277, no. 24, doi:10.1074/jbc.C200176200, ISSN 0021-9258, pages 21453 - 21457, XP002264445 |
| OPPOSITION | - Bielekova B , Martin R, "Development of biomarkers in multiple sclerosis", Brain, GB , (20040101), vol. 127, no. 7, doi:10.1093/brain/awh176, ISSN 0006-8950, pages 1463 - 1478, XP003014845 |
| OPPOSITION | - KOVARIK et al., "Overview of FTY720 Clinical Pharmacokinetics and Pharmacology", Therapeutic Drug Monitoring, (20040000), vol. 26, no. 6, doi:10.1097/00007691-200412000-00001, pages 585 - 587, XP055974234 |
| OPPOSITION | - Kovarik John M., Schmouder Robert L., Slade Alan J., "Overview of FTY720 Clinical Pharmacokinetics and Pharmacology : ", THERAPEUTIC DRUG MONITORING., Lippincott Williams and Wilkins., NEW YORK, NY, US, NEW YORK, NY, US , (20041201), vol. 26, no. 6, doi:10.1097/00007691-200412000-00001, ISSN 0163-4356, pages 585 - 587, XP055974234 |
| OPPOSITION | - Kahan Barry D; Karlix Janet L; Ferguson Ronald M; Leichtman Alan B; Mulgaonkar Shamkant; Gonwa Thomas A; Skerjanec Andrej; Schmouder Robert L; Chodoff Lawrence, "Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study", Transplantation, GB , (20031015), vol. 76, no. 7, doi:10.1097/01.TP.0000084822.01372.AC, ISSN 0041-1337, pages 1079 - 1084, XP009176760 |
| OPPOSITION | - Kahan Barry D; Karlix Janet L; Ferguson Ronald M; Leichtman Alan B; Mulgaonkar Shamkant; Gonwa Thomas A; Skerjanec Andrej; Schmouder Robert L; Chodoff Lawrence, "Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study", Transplantation, Williams and Wilkins, GB, GB , (20031015), vol. 76, no. 7, doi:10.1097/01.TP.0000084822.01372.AC, ISSN 0041-1337, pages 1079 - 1084, XP009176760 |
| OPPOSITION | - KAHAN B.D. et al., "Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I stud y", Transplantation, (20030000), vol. 76, doi:10.1097/01.TP.0000084822.01372.AC, pages 1079 - 1084, XP009176760 |
| OPPOSITION | - KAHAN et al., "Pharmacodynamics, Pharmacokinetics, and Safety of Multiple Doses of FTY20 in Stable Renal Transplant Patients: a Multicenter, Randomized, Placebo-Controlled, Phase I Study", Transplantation, (20030000), vol. 76, doi:10.1097/01.TP.0000084822.01372.AC, pages 1079 - 1084, XP009176760 |
| OPPOSITION | - KAHAN et al., "Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study", Transplantation, (20021015), vol. 76, no. 7, doi:10.1097/01.TP.0000084822.01372.AC, pages 1079 - 1084, XP009176760 |
| OPPOSITION | - KAHAN et al., "Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study", Transplantation, (20030000), vol. 76, no. 7, doi:10.1097/01.TP.0000084822.01372.AC, pages 1079 - 1084, XP009176760 |
| OPPOSITION | - John M. Kovarik; Robert Schmouder; Denise Barilla; Yibin Wang; Gerolf Kraus, "Single‐dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects", British journal of clinical pharmacology, BLACKWELL SCIENTIFIC PUBL., GB, GB , (20040323), vol. 57, no. 5, doi:10.1111/j.1365-2125.2003.02065.x, ISSN 0306-5251, pages 586 - 591, XP071598693 |
| OPPOSITION | - John M. Kovarik; Robert Schmouder; Denise Barilla; Yibin Wang; Gerolf Kraus, "Single‐dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects", British journal of clinical pharmacology, GB , (20040323), vol. 57, no. 5, doi:10.1111/j.1365-2125.2003.02065.x, ISSN 0306-5251, pages 586 - 591, XP071598693 |
| OPPOSITION | - Klemens Budde; Manuela Schütz; Petra Glander; Harm Peters; Johannes Waiser; Lutz Liefeldt; Hans‐H Neumayer; Torsten Böhler, "FTY720 (fingolimod) in renal transplantation", Clinical transplantation, DK , (20061107), vol. 20, doi:10.1111/j.1399-0012.2006.00596.x, ISSN 0902-0063, pages 17 - 24, XP071752520 |
| OPPOSITION | - Klemens Budde; Manuela Schütz; Petra Glander; Harm Peters; Johannes Waiser; Lutz Liefeldt; Hans‐H Neumayer; Torsten Böhler, "FTY720 (fingolimod) in renal transplantation", CLINICAL TRANSPLANTATION, DK , (20061107), vol. 20, doi:10.1111/j.1399-0012.2006.00596.x, ISSN 0902-0063, pages 17 - 24, XP071752520 |
| OPPOSITION | - Cris S Constantinescu, Nasr Farooqi, Kate O'brien, Bruno Gran, "Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)", British Journal of Pharmacology, Nature Pub. Group, etc., (20111001), vol. 164, no. 4, doi:10.1111/j.1476-5381.2011.01302.x, ISSN 00071188, pages 1079 - 1106, XP055216575 |
| OPPOSITION | - Cris S Constantinescu; Nasr Farooqi; Kate O'Brien; Bruno Gran, "Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)", British journal of pharmacology, Wiley-Blackwell, UK, UK , (20120209), vol. 164, no. 4, doi:10.1111/j.1476-5381.2011.01302.x, ISSN 0007-1188, pages 1079 - 1106, XP071035763 |
| OPPOSITION | - Guy M.L. Meno-Tetang, Hongshan Li Et Al, "Physiologically Based Pharmacokinetic Modeling of FTY720 (2-Amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in Rats After Oral and Intravenous Doses", Drug Metabolism and Disposition, (20060101), vol. 34, no. 9, doi:10.1124/dmd.105.009001, pages 1480 - 1487, XP055631799 |
| OPPOSITION | - MENO-TETANG et al., "Physiologically Based Pharmacokinetic Modeling of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in Rats After Oral and Intravenous Doses", Drug Metabolism and Disposition, (20060000), vol. 34, no. 9, doi:10.1124/dmd.105.009001, pages 1480 - 1487, XP055631799 |
| OPPOSITION | - FUJINO et al., "Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment", Journal of Pharmacology and experimental Therapeutics, (20030000), vol. 305, doi:10.1124/jpet.102.045658, pages 70 - 77, XP009022804 |
| OPPOSITION | - FUJINO et al., "Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment", The Journal of Pharmacology and Experimental Therapeutics, (20030000), vol. 305, doi:10.1124/jpet.102.045658, pages 70 - 77, XP009022804 |
| OPPOSITION | - FUJINO et al., "Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment", The Journal of Pharmacology and Experimental Therapeutics, (20030000), vol. 305, no. 1, doi:10.1124/jpet.102.045658, pages 70 - 77, XP009022804 |
| OPPOSITION | - FUJINO M, ET AL., "AMELIORATION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS IN LEWIS RATS BY FTY720 TREATMENT", Journal of pharmacology and experimental therapeutics, American Society for Pharmacology and Experimental Therapeutics, US, US , (20030401), vol. 305, no. 01, doi:10.1124/jpet.102.045658, ISSN 0022-3565, pages 70 - 77, XP009022804 |
| OPPOSITION | - FORREST et al., "Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1- Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Sub- types", The Journal of Pharmacology and Experimental Therapeutics, (20040000), vol. 309, no. 2, pages 758 - 768, XP055325255 |
| OPPOSITION | - FORREST M. J. et al., "Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes", Journal of Pharmacology and Experimental Therapeutics, (20040000), vol. 309, doi:10.1124/jpet.103.062828, pages 758 - 768, XP055325255 |
| OPPOSITION | - M. Forrest, "Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes", Journal of pharmacology and experimental therapeutics, American Society for Pharmacology and Experimental Therapeutics, US, US , (20040206), vol. 309, no. 2, doi:10.1124/jpet.103.062828, ISSN 0022-3565, pages 758 - 768, XP055325255 |
| OPPOSITION | - LAMONTAGNE KENNETH ET AL, "Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization", Cancer research, American Association for Cancer Research, US, US, (20060101), vol. 66, no. 1, doi:10.1158/0008-5472.CAN-05-2001, ISSN 0008-5472, pages 221 - 231, XP002498250 |
| OPPOSITION | - Ho Joanna W.Y., Man Kwan, Sun Chris K., Lee Terence K., Poon Ronnie T.P., Fan Sheung Tat, "Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20050901), vol. 4, no. 9, doi:10.1158/1535-7163.MCT-05-0021, ISSN 1535-7163, pages 1430 - 1438, XP093009612 |
| OPPOSITION | - John M. Kovarik et al., "Multiple-Dose FRY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects", Journal in Clinical Pharmacology, (2004), vol. 44, doi:10.1177/0091270004264165, XP055974243 |
| OPPOSITION | - KOVARIK et al., "Multiple-Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects", J Clin Pharmacol, (20040000), vol. 44, doi:10.1177/0091270004264165, pages 532 - 537, XP055974243 |
| OPPOSITION | - KOVARIK et al., "Multiple-Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects", Journal of Clinical Pharmacolog y, (20040000), vol. 44, doi:10.1177/0091270004264165, pages 532 - 537, XP055974243 |
| OPPOSITION | - KOVARIK et al., "Multiple-Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects", Journal of Clinical Pharmacology, (20040000), vol. 44, doi:10.1177/0091270004264165, pages 532 - 537, XP055974243 |
| OPPOSITION | - Kovarik et al. null, "Multiple-Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects", Journal of Clinical Pharmacology, (2004), vol. 44, doi:10.1177/0091270004264165, XP055974243 |
| OPPOSITION | - Kovarik John M., Schmouder Robert, Barilla Denise, Riviere Gilles-Jacques, Wang Yibin, Hunt Thomas, "Multiple-Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects", The Journal of clinical pharmacology, LIPPINCOTT CO, HAGERSTOWN, MD, US, US , (20040501), vol. 44, no. 5, doi:10.1177/0091270004264165, ISSN 0091-2700, pages 532 - 537, XP055974243 |
| OPPOSITION | - Andrej Skerjanec, Helio Tedesco, Hans-H. Neumayer, Edward Cole, Klemens Budde, Chyi-Hung Hsu, Robert Schmouder, "FTY720, a Novel Immunomodulator in de Novo Kidney Transplant Patients: Pharmacokinetics and Exposure-Response Relationship", The Journal of clinical pharmacology, LIPPINCOTT CO, HAGERSTOWN, MD, US, US , (20051101), vol. 45, no. 11, doi:10.1177/0091270005279799, ISSN 0091-2700, pages 1268 - 1278, XP055631804 |
| OPPOSITION | - SKERJANEC et al., "FTY 720, a Novel Immunomodulator in de Novo Kidney Transplant Patients; Pharmacokinetics and Exposure-Response Relationship", J. Clin. Pharmacol., (20050000), vol. 45, no. 1, doi:10.1177/0091270005279799, pages 1268 - 1278, XP055631804 |
| OPPOSITION | - SKERJANEC et al., "FTY720, a Novel Immunomodulator in de Novo Kidney Transplant Patients: Pharmacokinetics and Exposure-Response Relationship", Journal of Clinical Pharmacology, (20050000), vol. 45, doi:10.1177/0091270005279799, pages 1268 - 1278, XP055631804 |
| OPPOSITION | - Kovarik, Et Al., "Oral Presentations", Multiple Sclerosis Journal, Sage, US, US , (20050901), vol. 11, no. 5_suppl, doi:10.1191/1352458505ms1258xx, ISSN 1352-4585, pages S1 - S182, XP093004709 |
| OPPOSITION | - KURTZKE J.F., "Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS", Neurology, (19830000), vol. 33, doi:10.1212/WNL.33.11.1444, pages 1444 - 1452, XP009186641 |
| OPPOSITION | - KURTZKE J F, "RATING NEUROLOGIC IMPAIRMENT IN MULTIPLE SCLEROSIS AN EXPANDED DISABILITY STATUS SCALE", Neurology, Lippincott Williams & Wilkins , Philadelphia, US, US , (19830101), vol. 33, no. 11, doi:10.1212/WNL.33.11.1444, ISSN 0028-3878, pages 1444 - 1452, XP009186641 |
| OPPOSITION | - KURTZKE, "Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS", Neurology, (19830000), vol. 33, doi:10.1212/WNL.33.11.1444, pages 1444 - 1452, XP009186641 |
| OPPOSITION | - HORGA A et al., "FTY729 (fingolimod) for relapsing multiple sclerosis", Expert Rev. Neurotherapeutics, (20080000), vol. 8, no. 5, doi:10.1586/14737175.8.5.699, pages 699 - 714, XP009121786 |
| OPPOSITION | - Park et al. null, "Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients", Brazilian Journal of Medical and Biological Research , (2005), vol. 38, doi:10.1590/S0100-879X2005000500005, XP055974218 |
| OPPOSITION | - P ARK et al., "Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients", Brazilian Journal of Medical and Biological Research, (20050000), vol. 38, doi:10.1590/S0100-879X2005000500005, pages 683 - 694, XP055974218 |
| OPPOSITION | - PARK et al., "Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients", Brazilian Journal of Medical and Biological Research, (20050000), vol. 38, doi:10.1590/S0100-879X2005000500005, pages 683 - 694, XP055974218 |
| OPPOSITION | - PARK et al., "Pharmacokinetic/Pharmacodynamic Relationships of FTY720 in Kidney Transplant Recipients", Brazilian Journal of Medical and Biological Research, (20050000), vol. 38, doi:10.1590/S0100-879X2005000500005, pages 683 - 694, XP055974218 |
| OPPOSITION | - PARK S. I. et al., "Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients", Brazilian Journal of Medical and Biological Research, (20050000), vol. 38, doi:10.1590/S0100-879X2005000500005, pages 683 - 694, XP055974218 |
| OPPOSITION | - Park S.I., Felipe C.R., Machado P.G., Garcia R., Skerjanec A., Schmouder R., Tedesco-Silva Jr. H., Medina-Pestana J.O., "Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients", Brazilian Journal of Medical and Biological Research, (20050501), vol. 38, no. 5, doi:10.1590/S0100-879X2005000500005, ISSN 0034-7310, pages 683 - 694, XP055974218 |
| OPPOSITION | - Park S.I., Felipe C.R., Machado P.G., Garcia R., Skerjanec A., Schmouder R., Tedesco-Silva Jr. H., Medina-Pestana J.O., "Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients", Brazilian Journal of Medical and Biological Research, Associação Brasileira de Divulgação CientÃfica, (20050501), vol. 38, no. 5, doi:10.1590/S0100-879X2005000500005, ISSN 0034-7310, pages 683 - 694, XP055974218 |
| OPPOSITION | - S.I. Park et al., "Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients", Brazilian Journal of Medical and Biological Research, (2005), vol. 38, doi:10.1590/S0100-879X2005000500005, XP055974218 |
| OPPOSITION | - Katz Russell, "Biomarkers and Surrogate Markers: An FDA Perspective", The Journal of the American Society for Experimental NeuroTherapeutics, (20040401), vol. 1, no. 2, doi:10.1602/neurorx.1.2.189, ISSN 1545-5343, pages 189 - 195, XP005871682 |
| OPPOSITION | - Janet Freilich, "Prophetic Patents", SSRN Electronic Journal, Social Science Research Network, US, US , (20190614), vol. 364, no. 6445, doi:10.2139/ssrn.3202493, ISSN 1556-5068, pages 1036 - 1037, XP093163208 |
| OPPOSITION | - Skundric D., "Experimental Models of Relapsing-Remitting Multiple Sclerosis: Current Concepts and Perspective", Current neurovascular research, Bentham Science Publishers Ltd, NL, NL , (20051001), vol. 2, no. 4, doi:10.2174/156720205774322601, ISSN 1567-2026, pages 349 - 362, XP055975782 |
| OPPOSITION | - SKUNDRIC, DUSANKA S., "Experimental Models of Relapsing-Remitting Multiple Sclero- sis: Current concepts and Perspectives", Current Neurovascular Research, (20050000), vol. 2, no. 4, pages 1 - 14, XP055975782 |
| OPPOSITION | - HE et al., "Effect of 2-amino-2-[2-(4-octylphenyl) ethyl] propane-1,3-diol hydrochloride (FTY 720) on immune liver injury in mice", World J Gastroenterol, (20050000), vol. 11, no. 4, doi:10.3748/wjg.v11.i4.573, pages 573 - 576, XP055619707 |
| OPPOSITION | - HE et al., "Effect of 2-amino-2-[2-(4-octylphenyl) ethyl] propane-1,3-diol hydrochloride (FTY 720) on immune liver injury in mice", World Journal of Gastroenterology, (20050000), vol. 11, no. 4, doi:10.3748/wjg.v11.i4.573, pages 573 - 576, XP055619707 |
| OPPOSITION | - HE et al., "Effect of 2-amino-2-[2-(4-octylphenyl) ethyl] propane-1,3-diol hydrochlo- ride (FTY 720) on immune liver injury in mice", World Journal of Gastroenterology, (20050000), vol. 11, no. 4, pages 573 - 576, XP055619707 |
| OTHER | - "4083 Fingolimod", Maryadele J. O'Neil et al, The Merck Index. 14th ed., MERCK & Co., INC., (2006), page 697, ISBN 978-0-911910-00-1, XP055619728 |
| OTHER | - Anonymous, "lmmunmodulator FlY 720: Viel versprechend bei multipler Sklerose", Deutsche Apotheker Zeitung, (20050626), page 47, URL: https://www.deutsche-apotheker-zeitung.de/daz-az/2005/daz-26-2005/uid-14188, XP055619742 |
| OTHER | - CHIBA et al., "Role of Sphingosine 1-Phosphate Receptor Type 1 in Lymphocyte Egress from Secondary Lymphoid Tissues and Thymus", Cellular & Molecular Immunology, (20060200), vol. 3, no. 1, pages 11 - 19, XP055619721 |
| OTHER | - BUDDE et al., "Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients", Am. J. Transplant., (20030700), vol. 3, no. 7, pages 846 - 854, XP055664232 |
| OTHER | - BRINKMANN VOLKER ET AL, "The immune modulator FTY720 targets sphingosine 1-phosphate receptors", J. Biolog. Chem., (20020614), vol. 277, no. 24, pages 21453 - 21453, XP002264445 |
| OTHER | - MENO-TETANG GMLI HMIS SPYSZCZYNSKI NHEINING PLOWE PJUSKO WJ, "Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses", Drug Metab Dispos., (20060900), vol. 34, no. 9, pages 1480 - 1487, XP055631799 |
| OTHER | - SKERJANEC A et al., "FTY720, a Novel Immunomodulator in de Novo Kidney Transplant Patients: Pharmacokinetics and Exposure-Response Relationship", Journal of Clinical Pharmacology, (20050000), vol. 45, pages 1268 - 1278, XP055631804 |
| OTHER | - Jing-Hua He et al, "Effect of 2-amino-2-[2-(4-octylphenyl) ethyl] propane-1,3-diol hydrochloride (FTY 720) on immune liver injury in mice", World J Gastroenterol, (20050128), vol. 11, no. 4, pages 573 - 576, XP055619707 |
| SEARCH | - BRINKMANN VOLKER ET AL, "The immune modulator FTY720 targets sphingosine 1-phosphate receptors", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, (20020614), vol. 277, no. 24, ISSN 0021-9258, pages 21453 - 21457, XP002264445 [X] 1-3,7-11 * the whole document * * page 21457, column 1, line 44 - line 53 * [Y] 1-11 |
